Drug eluting balloon followed BMS versus DES in de novo lesions

Original title: Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: A randomized trial. Reference: Francesco Liistro et al. Am Heart J 2013;166:920-6. Recently, drug eluting balloons (DEB) have emerged as a potential alternative to drug-eluting stents (DES). Paclitaxel is an appropriate drug for DEBs given<a href="https://solaci.org/en/2013/12/03/drug-eluting-balloon-followed-bms-versus-des-in-de-novo-lesions/" title="Read more" >...</a>

Alvimedica merges with CID, Italy’s leading high tech company specialized in cardiology

Alvimedica fusiona con CID, la empresa líder de alta tecnología italiana especializada en cardiología En línea con su estrategia de convertirse en una de las cinco mayores empresas del mercado mundial en su sector, Alvimedica, exclusivo de la marca en todo el mundo de Turquía en la cardiología intervencionista, se ha fusionado con la innovadora<a href="https://solaci.org/en/2013/12/02/alvimedica-merges-with-cid-italys-leading-high-tech-company-specialized-in-cardiology-2/" title="Read more" >...</a>

Infrapatellar balloon angioplasty, the easiest option and with better results in critical ischemia with tissue loss

Original title: Longitudinal outcomes After Tibioperoneal Angioplasty Alone Compared to Tibial Stenting and Atherectomy for Critical Limb ischemia. Reference: Shaun Reynolds et al. Vascular and and Endovascular Surgery 2013 47(7):507-512 The Infrapatellar peripheral vascular disease has increased in recent years, relating to tissue loss and amputation. The therapeutic strategy is not clear, let alone the use of stents<a href="https://solaci.org/en/2013/11/21/infrapatellar-balloon-angioplasty-the-easiest-option-and-with-better-results-in-critical-ischemia-with-tissue-loss/" title="Read more" >...</a>

Noncardiac surgery is safe after 6 months after implantation of a DES

Original title: Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. Reference: Hawn MT et al. JAMA 2013;DOI:10.1001 In the patients who underwent non cardiac surgery and had coronary angioplasty with stent history  within 2 years there was not increased in major cardiac events (MACE ) with the exception of those who were<a href="https://solaci.org/en/2013/10/11/noncardiac-surgery-is-safe-after-6-months-after-implantation-of-a-des/" title="Read more" >...</a>

Endoprosthesis for the treatment of type A aortic dissection

Original title: Application of Open Triple-Branch Aortic Arch Stent Graff for Acute Stanford Type A Aortic Dissection Reference: Fei Hua, et; al. Vascular Endovascular Surgery 47;2:109-14 Type A aortic dissection is a disease of high morbidity and mortality, especially in the early hours . Surgery is the treatment of choice but still have a significant complication rate .<a href="https://solaci.org/en/2013/10/08/endoprosthesis-for-the-treatment-of-type-a-aortic-dissection/" title="Read more" >...</a>

Cilostazol reduces restenosis of DES in lesions larger than 40 mm.

Original title: Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the Pooled Analysis of DECLARE Trials). Reference: Seung-Whan Lee et al. Am J Cardiol 2013, article in press. Cilostazol, an inhibitor of phosphodiesterase III , associated with aspirin and clopidogrel showed decrease angiographic restenosis both in conventional stents as well as<a href="https://solaci.org/en/2013/10/07/cilostazol-reduces-restenosis-of-des-in-lesions-larger-than-40-mm/" title="Read more" >...</a>

Paclitaxel eluting balloon . More effective in restenosis of BMS than DES

Original title: A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Referencia: Seiji Habara et al. Am Heart J 2013;166:527-533.e2. Paclitaxel – eluting balloons have recently emerged as an option for treating in-stent restenosis, both conventional stents ( BMS ) and with drugs (DES ).<a href="https://solaci.org/en/2013/09/25/paclitaxel-eluting-balloon-more-effective-in-restenosis-of-bms-than-des/" title="Read more" >...</a>

Usefulness of FFR in coronary bypass intermediate lesions

Original title: Long-term clinical outcome after fractional flow reserve– versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. Reference: Luigi Di Serafino et al. Am Heart J 2013;166:110-8. Bypass coronary angioplasty is often preferred strategy versus re-operation , however it is associated with a greater number of events,  both short and long<a href="https://solaci.org/en/2013/09/24/usefulness-of-ffr-in-coronary-bypass-intermediate-lesions/" title="Read more" >...</a>

Everolimus Eluting Stent in multiple vessels with short SYNTAX score

Original title: A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease. The EXECUTIVE (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease) Trial. Reference: Flavio Ribichini et al. J Am Coll Cardiol Intv 2013. Article in press. Drug-eluting stents (DES ) have emerged<a href="https://solaci.org/en/2013/09/24/everolimus-eluting-stent-in-multiple-vessels-with-short-syntax-score/" title="Read more" >...</a>

Difference in mortality with surgery versus angioplasty in diabetic multivessel patients

Original title: Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: A meta-analysis of randomized controlled trials. Reference: Verma S. et al. Lancet Diabetes Endocrinol. 2013;Epub ahead of print. The FREEDOM study was the last of the randomized studies that compared the results of surgery versus coronary angioplasty in diabetic multivessel patients showing a<a href="https://solaci.org/en/2013/09/18/difference-in-mortality-with-surgery-versus-angioplasty-in-diabetic-multivessel-patients/" title="Read more" >...</a>